Submit a Release
Home
All
ESG
Health
Technology
Finance
Contributors
Sub Menu
Submit a Release
main-search-pop
Main menu
BioArctic collaborator Novartis terminates agreement
Contributed by:
PR Newswire
Tags
BioArctic
More Like This
BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties
BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology
BioArctic and Eisai sign research evaluation agreement regarding BAN2802
BrainTransporter™ dramatically improves antibody delivery to the brain
BioArctic and Mesenkia enter oncology research collaboration
BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
BioArctic's founders intend to divest minor part of their shareholding
